Interact with experts and peers.

Recent Posts

10 of 12 Shown
  • Biosimilars: Addressing Uncertainties With a New Drug Class

    Kenneth G. Saag MD, MSc - 3/13/2017 2 comments / Last Comment: 4/24/2017
    Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.
  • Targeting IL-17 in Psoriatic Arthritis: Key Data From the 2016 ACR Meeting

    Arthur Kavanaugh MD - 2/1/2017 1 comment / Last Comment: 2/2/2017
    The 2016 American College of Rheumatology annual meeting gave us promising data on agents targeting IL-17 in psoriatic arthritis. Here’s my take on select abstracts.
  • JAK Inhibitors in Rheumatoid Arthritis: Weighing the Anticipated Options

    Roy Fleischmann MD - 9/9/2016 1 comment / Last Comment: 12/15/2016
    Clinical trial data to date have shown tofacitinib and baricitinib to be largely similar in efficacy and safety. But are there meaningful differences that might help clinicians choose between them? Here’s my take.
  • My Take on New ASAS/EULAR Recommendations for Managing Axial Spondyloarthritis

    Atul Deodhar MD - 7/22/2016
    I describe noteworthy differences between the newly updated ASAS/EULAR recommendations and the ACR/SAA/SPARTAN recommendations.
  • New Developments in Ankylosing Spondylitis from EULAR 2016

    Atul Deodhar MD - 7/15/2016 1 comment / Last Comment: 8/13/2016
    Dr. Atul Deodhar reviews new insights into the pathogenesis of AS and clinical trial updates that may affect your practice.
  • Tapering Therapy in Rheumatoid Arthritis: My Approach

    Eric M. Ruderman MD - 7/14/2016 3 comments / Last Comment: 12/15/2016
    Consideration of tapering RA therapy is a careful balance between sustained remission and drug tolerability. Here is my take on determining when it is appropriate and which agents to taper.
  • Reconsidering the Role of Glucocorticoids in Rheumatoid Arthritis Management

    Gregg J. Silverman MD - 6/9/2016 5 comments / Last Comment: 12/15/2016
    The updated ACR guideline encourages us to reconsider the use of glucocorticoids for patients with RA. Here’s my take.
  • How I Use Musculoskeletal Ultrasound in the Management of My Rheumatoid Arthritis Patients

    Cesar E. Fors Nieves MD - 4/21/2016 5 comments / Last Comment: 12/15/2016
    Musculoskeletal ultrasound is a great tool for monitoring patients’ disease and specifically for visualizing disease damage and subclinical inflammation.
  • Emerging Treatments for Rheumatoid Arthritis: How Will They Fit In?

    Stanley B. Cohen MD - 9/29/2015 2 comments / Last Comment: 2/13/2016
    Several new and investigational therapeutics are expanding treatment options for patients with RA. But how each will fit into the current treatment paradigm is not yet clear.
  • Progress in Treating Axial Spondyloarthritis: My Thoughts on Novel Therapeutic Agents

    Atul Deodhar MD - 2/6/2015 2 comments / Last Comment: 3/17/2017
    Research presented at the 2014 ACR annual meeting showed that targeting the IL-23/IL-17 axis in ankylosing spondylitis led to high ASAS20 responses, and the use of TNF inhibitors benefits patients with nonradiographic axial spondyloarthritis.
10 of 12 Shown
Show 2 More